This penny stock is up 500% since January 2020. Should I buy now?

The E-Therapeutics share price is surging following its latest results. Is now the time to buy the penny stock? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of E-Therapeutics (LSE:ETX) was on fire throughout all of 2020 and has continued to rise since. The penny stock was priced at 3.75p back in January last year. But today is much closer to 23p. What caused this 510% surge? And should I be adding the business to my portfolio? Let’s take a look.

A tech solution to drug development

E-Therapeutics is involved in the drug discovery sector of the pharmaceutical industry. Discovering and creating new medicines is a long and expensive process that carries a lot of risks. However, this software company is trying to help change that.

It has developed a proprietary platform that incorporates big data and a suite of powerful tools driven by artificial intelligence to accelerate the drug discovery process. And while the technology only recently launched, it is already being used to investigate type-2 diabetes as well as neurodegeneration diseases such as Alzheimer’s and Parkinson’s.

Why is the penny stock on the rise?

The E-Therapeutics share price started to climb in early 2020, following the release of its results for 2019. It had been a pre-revenue business for many years, and so finally, seeing some form of revenue was exciting. What’s more, overall losses for the year were cut in half, from £5.1m in 2018 to £2.9m in 2019. Combined, this appears to be the primary catalyst for the rising share price. However, I’m far more interested in another announcement made later in the year.

In May, E-Therapeutics announced it had expanded its platform’s capabilities to support RNA interference (RNAi). Without going too deeply into gene science, RNAi enables the manipulation of protein behaviour within the body. RNAi-based therapies can treat a wide range of diseases such as cancer and antibiotic-resistant bacterial infections.

Today the RNAi drug market is worth approximately $39bn. But current forecasts indicate it will grow by an average of 27.2% annually, reaching a market size of $131bn by 2025. Needless to say, that represents an enormous growth opportunity for this penny stock.

Risks to consider

As promising as the technology may be, there are some significant risks to consider. The first being the lack of substantial revenue. In 2020, the firm only generated £0.5m, which doesn’t come close to covering the cost of operations. As such, the business is still dependent on outside funding to keep the lights on.

What’s more, the company is exposed to some significant cyber-security threats. If a breach were to occur that exposed sensitive client data, E-Therapeutics’ reputation could be severely damaged, leading to a potentially significant reduction in future revenue.

The E-Therapeutics share price is a penny stock

The bottom line: a penny stock to buy?

The company’s technology is rather impressive in my eyes, especially given the growth opportunities that lie before it. However, even with its recent progress, I believe it’s too soon to invest, especially at its current share price. The market capitalisation of the stock is almost £100m, despite it only generating a tiny amount of revenue. Therefore I’m not adding E-Therapeutics to my portfolio today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in E-Therapeutics. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »